Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy

References

• Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012 Jun 14;10(6):717–728. PubMed PMID: 22704512.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ .Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer. 2008 Oct;8(10):755–768. PubMed PMID: 18784658.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Stem cells and cancer - the promise and puzzles. Mol Oncology. 2010 Oct;4(5):369–372. PubMed PMID: 20692213.
   PubMed Web of Science ®Google Scholar
• Somervaille TC, Matheny CJ, Spencer GJ, et al.Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell. 2009 Feb 6;4(2):129–140. PubMed PMID: 19200802. Pubmed Central PMCID: 2670853.
   PubMed Web of Science ®Google Scholar
• Visvader JE. Cells of origin in cancer. Nature. 2011 Jan 20;469(7330):314–322. PubMed PMID: 21248838.
   PubMed Web of Science ®Google Scholar
• Schepers AG, Snippert HJ, Stange DE, et al.Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science (New York, NY). 2012 Aug 10;337(6095):730–735. PubMed PMID: 22855427. Epub 2012/08/03. eng. 10.1126/science.1224676
   Google Scholar
• Valent P, Bonnet D, De Maria R, et al.Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer. 2012 Nov; 12(11):767–775. PubMed PMID: 23051844.
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Ginestier C, Bertucci F, et al.ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Research. 2013 Dec 15;73(24):7290–7300. PubMed PMID: 24142344. Epub 2013/10/22. eng. 10.1158/0008-5472.CAN-12-4704
   PubMed Web of Science ®Google Scholar
• Visvader JE, Clevers H. Tissue-specific designs of stem cell hierarchies. Nature Cell Biology. 2016 Apr;18(4):349–355. PubMed PMID: 26999737. 10.1038/ncb3443
   PubMed Web of Science ®Google Scholar
• Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008 Dec 4;456(7222):593–598. PubMed PMID: 19052619. Pubmed Central PMCID: 2597380. 10.1038/nature07567
   PubMed Web of Science ®Google Scholar
• Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009 Sep 4;138(5):822–829. PubMed PMID: 19737509.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen C, Van Der Horst G, Cheung H, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Research. 2010 Jun 15;70(12):5163–5173. PubMed PMID: 20516116. 10.1158/0008-5472.CAN-09-3806
   PubMed Web of Science ®Google Scholar
• Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. Plos One. 2009;4(12):e8377. PubMed PMID: 20027313. Pubmed Central PMCID: PMC2793431. Epub 2009/12/23. eng. 10.1371/journal.pone.0008377
   Google Scholar
• Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Research. 2007 Feb 1;67(3):1030–1037. PubMed PMID: 17283135. Epub 2007/02/07. eng. 10.1158/0008-5472.CAN-06-2030
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, et al.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007 Nov; 1(5):555–567. PubMed PMID: 18371393. Pubmed Central PMCID: PMC2423808. Epub 2008/03/29. eng. 10.1016/j.stem.2007.08.014
   PubMed Web of Science ®Google Scholar
• Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2009 Jun 15;15(12):4234–4241. PubMed PMID: 19509181. Epub 2009/06/11. eng. 10.1158/1078-0432.CCR-09-0547
   PubMed Web of Science ®Google Scholar
• Lim SH, Jang J, Park JO, et al.CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of Gastrointestinal Oncology. 2014 Dec;5(6):447–456. PubMed PMID: 25436124. Pubmed Central PMCID: PMC4226826. Epub 2014/12/02. eng.
   PubMedGoogle Scholar
• Rasheed ZA, Yang J, Wang Q, et al.Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Institute. 2010 Mar 3;102(5):340–351. PubMed PMID: 20164446. Pubmed Central PMCID: 2831049. 10.1093/jnci/djp535
   PubMedGoogle Scholar
• Canter RJ, Ames E, Mac S, et al.Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer. 2014;14:756. PubMed PMID: 25301268. Pubmed Central PMCID: 4200119. 10.1186/1471-2407-14-756
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012 Aug 23;488(7412):522–526. PubMed PMID: 22854781. Pubmed Central PMCID: 3427400.
   PubMed Web of Science ®Google Scholar
• De Sousa EMF, Wnt VL. Signaling in Cancer Stem Cell Biology. Cancers. 2016 Jun 27;8(7):1–18. PubMed PMID: 27355964. Pubmed Central PMCID: 4963802.
   Google Scholar
• Matsui WH. Cancer stem cell signaling pathways. Medicine. 2016 Sep;95(1 Suppl 1):S8–S19. PubMed PMID: 27611937. 10.1097/MD.0000000000004765
   PubMed Web of Science ®Google Scholar
• Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2016 Sep 12. PubMed PMID: 27617575. 10.1038/onc.2016.304
   Google Scholar
• Magni M, Shammah S, Schiro R, et al. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996 Feb 1;87(3):1097–1103. PubMed PMID: 8562935.
   PubMed Web of Science ®Google Scholar
• Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011 Jun;7(2):292–306. PubMed PMID: 21103958. 10.1007/s12015-010-9208-4
   PubMed Web of Science ®Google Scholar
• Singh S, Brocker C, Koppaka V, et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radical Biology & Medicine. 2013 Mar;56:89–101. PubMed PMID: 23195683. Pubmed Central PMCID: 3631350. 10.1016/j.freeradbiomed.2012.11.010
   PubMed Web of Science ®Google Scholar
• Caputo E, Maiorana L, Vasta V, et al. Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle. 2011 May 1;10(9):1378–1384. PubMed PMID: 21552008. 10.4161/cc.10.17.17068
   PubMed Web of Science ®Google Scholar
• Thapa R, Wilson GD. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells International. 2016;2016:2087204. PubMed PMID: 27200096. Pubmed Central PMCID: 4856920.
   Google Scholar
• Toole BP, Slomiany MG. Hyaluronan, CD44 and emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008 Jun;11(3):110–121. PubMed PMID: 18490190. Pubmed Central PMCID: PMC2584579. 10.1016/j.drup.2008.04.002
   PubMed Web of Science ®Google Scholar
• Grosse-Gehling P, Fargeas CA, Dittfeld C, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013 Feb;229(3):355–378. PubMed PMID: 22899341. 10.1002/path.4086
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 7;444(7120):756–760. PubMed PMID: 17051156. Epub 2006/10/20. eng. 10.1038/nature05376
   PubMed Web of Science ®Google Scholar
• Islam F, Gopalan V, Smith RA, et al. Translational potential of cancer stem cells: a review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp Cell Res. 2015 Jul 1;335(1):135–147. PubMed PMID: 25967525. 10.1016/j.yexcr.2015.04.018
   PubMed Web of Science ®Google Scholar
• Kim Y-M, Kahn M. The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development. Research and Reports in Biochemistry. 2014;4:1–12. PubMed PMID: 26566491. Pubmed Central PMCID: 4640466. 10.2147/RRBC.S53823
   PubMedGoogle Scholar
• Vermeulen L, De Sousa EMF, Van Der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010 May;12(5):468–476. PubMed PMID: 20418870. 10.1038/ncb2048
   PubMed Web of Science ®Google Scholar
• Howe LR, Watanabe O, Leonard J, et al. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003 Apr 15;63(8):1906–1913. PubMed PMID: 12702582.
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008 Jun;14(6):818–829. PubMed PMID: 18539112. 10.1016/j.devcel.2008.05.009
   PubMed Web of Science ®Google Scholar
• Page BB, Hamad B, Kirkpatrick P, et al. Dronedarone. Nat Rev Drug Discov. 2009 Oct;8(10):806–823. PubMed PMID: 19794444. 10.1038/nrd2998
   PubMed Web of Science ®Google Scholar
• Robertson FM, Ogasawara MA, Ye Z, et al. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen. 2010 Aug;15(7):820–829. PubMed PMID: 20639504. 10.1177/1087057110376541
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015 Nov;15(11):669–682. PubMed PMID: 26471778. 10.1038/nri3902
   PubMed Web of Science ®Google Scholar
• Dayan F, Mazure NM, Brahimi-Horn MC, et al. A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron. 2008 Dec;1(1):53–68. PubMed PMID: 19308685. Pubmed Central PMCID: PMC2654353. 10.1007/s12307-008-0006-3
   PubMedGoogle Scholar
• Seaman S, Stevens J, Yang MY, et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007 Jun;11(6):539–554. PubMed PMID: 17560335. Pubmed Central PMCID: PMC2039723. 10.1016/j.ccr.2007.04.017
   PubMed Web of Science ®Google Scholar
• Mulligan JK, Lathers DM, Young MR. Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions. Cancer Immunol Immunother 2008 Jul;57(7):951–961. PubMed PMID: 18058097. Pubmed Central PMCID: PMC3333838. 10.1007/s00262-007-0425-x
   PubMed Web of Science ®Google Scholar
• Zamora AE, Grossenbacher SK, Aguilar EG, et al. Models to Study NK Cell Biology and Possible Clinical Application. Current Protocols in Immunology /Edited by John E Coligan [Et Al]. 2015;110:1437 1–14. PubMed PMID: 26237009. Pubmed Central PMCID: 4772895.
   PubMedGoogle Scholar
• Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annual Review of Immunology. 2006;24:257–286. PubMed PMID: 16551250. 10.1146/annurev.immunol.24.021605.090700
   PubMed Web of Science ®Google Scholar
• Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005 Aug 4;436(7051):709–713. PubMed PMID: 16079848. 10.1038/nature03934
   PubMed Web of Science ®Google Scholar
• Cichocki F, Sitnicka E, Bryceson YT. NK cell development and function–plasticity and redundancy unleashed. Semin Immunol. 2014 Apr;26(2):114–126. PubMed PMID: 24594002. 10.1016/j.smim.2014.02.003
   PubMed Web of Science ®Google Scholar
• Foley B, Felices M, Cichocki F, et al. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014 Mar;258(1):45–63. PubMed PMID: 24517425. Pubmed Central PMCID: 3927144. 10.1111/imr.12157
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011 Jan 7;331(6013):44–49. PubMed PMID: 21212348. Pubmed Central PMCID: 3089969. 10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Romee R, Schneider SE, Leong JW, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012 Dec 6;120(24):4751–4760. PubMed PMID: 22983442. Pubmed Central PMCID: 3520618. 10.1182/blood-2012-04-419283
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine. 2016 Sep 21;8(357):357ra123. PubMed PMID: 27655849. 10.1126/scitranslmed.aaf0746
   PubMed Web of Science ®Google Scholar
• North J, Bakhsh I, Marden C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunology. 2007 Jan 1;178(1):85–94. PubMed PMID: 17182543. 10.4049/jimmunol.178.1.85
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008 May;9(5):495–502. PubMed PMID: 18425106. Pubmed Central PMCID: 2669298. 10.1038/ni1581
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol. 2001 Jun;20(3–4):503–534. PubMed PMID: 11878513.
   PubMedGoogle Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001 Nov;22(11):633–640. PubMed PMID: 11698225. 10.1016/S1471-4906(01)02060-9
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. The New England Journal of Medicine. 2012 Aug 30;367(9):805–816. PubMed PMID: 22931314. Pubmed Central PMCID: 3767478. 10.1056/NEJMoa1200503
   PubMed Web of Science ®Google Scholar
• Dambrauskas Z, Svensson H, Joshi M, et al. Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma. Int J Oncol. 2014 Jan;44(1):99–104. PubMed PMID: 24173243.
   PubMed Web of Science ®Google Scholar
• Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Reviews Immunol. 2008 Apr;8(4):259–268. PubMed PMID: 18340344. Pubmed Central PMCID: 2584366. 10.1038/nri2276
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001 Apr;13(4):459–463. PubMed PMID: 11282985. 10.1093/intimm/13.4.459
   PubMed Web of Science ®Google Scholar
• Haliotis T, Ball JK, Dexter D, et al. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. International Journal of Cancer. 1985 Apr 15;35(4):505–513. PubMed PMID: 2985510. 10.1002/ijc.2910350414
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Meyers KM, Prieur DJ, et al. Role of NK cells in tumour growth and metastasis in beige mice. Nature. 1980 Apr 17;284(5757):622–624. PubMed PMID: 7366733. 10.1038/284622a0
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001 Sep 13;413(6852):165–171. PubMed PMID: 11557981. Pubmed Central PMCID: 3900321. 10.1038/35093109
   PubMed Web of Science ®Google Scholar
• Good RA. Relations between immunity and malignancy. Proc Natl Acad Sci U S A. 1972 Apr;69(4):1026–1032. PubMed PMID: 4558479. Pubmed Central PMCID: 426620.
   PubMed Web of Science ®Google Scholar
• Kawarabayashi N, Seki S, Hatsuse K, et al. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology. 2000 Nov;32(5):962–969. PubMed PMID: 11050046. 10.1053/jhep.2000.19362
   PubMed Web of Science ®Google Scholar
• Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011 Jun;17(6):700–707. PubMed PMID: 21552268. 10.1038/nm.2366
   PubMed Web of Science ®Google Scholar
• Semeraro M, Rusakiewicz S, Zitvogel L, et al. Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. Oncoimmunology. 2015 Nov;4(11):e1042202. PubMed PMID: 26451315. Pubmed Central PMCID: 4589051. 10.1080/2162402X.2015.1008371
   Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013 Jun 15;73(12):3499–3510. PubMed PMID: 23592754. 10.1158/0008-5472.CAN-13-0371
   PubMed Web of Science ®Google Scholar
• Cichocki F, Cooley S, Davis Z, et al. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016 Feb;30(2):456–463. PubMed PMID: 26416461. Pubmed Central PMCID: 4740203. 10.1038/leu.2016.124
   PubMed Web of Science ®Google Scholar
• Kamimura H, Yamagiwa S, Tsuchiya A, et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol. 2012 Feb;56(2):381–388. PubMed PMID: 21756848. 10.1016/j.jhep.2011.06.017
   PubMed Web of Science ®Google Scholar
• Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 2011 Dec;3(12):1445–1459. PubMed PMID: 22091681. Pubmed Central PMCID: 3292871. 10.2217/imt.11.131
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. PubMed PMID: 3903508. 10.1056/NEJM198512053132327
   PubMed Web of Science ®Google Scholar
• Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985 Oct;75(4):595–603. PubMed PMID: 3876465.
   PubMedGoogle Scholar
• Rayner AA, Grimm EA, Lotze MT, et al. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 1985 Mar 15;55(6):1327–1333. PubMed PMID: 3871657.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051–3057. PubMed PMID: 15632206. 10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011 Jan;13(1):98–107. PubMed PMID: 20849361. Pubmed Central PMCID: 3760671. 10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Knorr DA, Bachanova V, Verneris MR, et al. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014 Apr;26(2):161–172. PubMed PMID: 24618042. Pubmed Central PMCID: 3984606. 10.1016/j.smim.2014.02.002
   PubMed Web of Science ®Google Scholar
• Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci United States America. 2000 Mar 14;97(6):2731–2736. PubMed PMID: 10694580. Pubmed Central PMCID: 15998. 10.1073/pnas.050588297
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Huergo-Zapico L, Galvan JA, et al. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunology. 2013 Apr 15;190(8):4408–4419. PubMed PMID: 23509364. 10.4049/jimmunol.1202950
   PubMed Web of Science ®Google Scholar
• Monjazeb AM, Zamora AE, Grossenbacher SK, et al. Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncology. 2013;3:197. PubMed PMID: 23898464. Pubmed Central PMCID: 3724213. 10.3389/fonc.2013.00197
   PubMedGoogle Scholar
• Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunology, Immunotherapy: CII. 2014 Jan;63(1):21–28. PubMed PMID: 23989217. Pubmed Central PMCID: 3880590. 10.1007/s00262-013-1469-8
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003 Aug 1;102(3):814–819. PubMed PMID: 12689936. 10.1182/blood-2003-01-0091
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002 Mar 15;295(5562):2097–2100. PubMed PMID: 11896281. 10.1126/science.1068440
   PubMed Web of Science ®Google Scholar
• Perez-Cunningham J, Ames E, Smith RC, et al. Natural killer cell subsets differentially reject embryonic stem cells based on licensing. Transplantation. 2014 May 27;97(10):992–998. PubMed PMID: 24704665. 10.1097/TP.0000000000000063
   PubMed Web of Science ®Google Scholar
• Tallerico R, Garofalo C, Carbone E. A New Biological Feature of Natural Killer Cells: The Recognition of Solid Tumor-Derived Cancer Stem Cells. Front Immunology. 2016;7:179. PubMed PMID: 27242786. Pubmed Central PMCID: 4861715. 10.3389/fimmu.2016.00177
   PubMed Web of Science ®Google Scholar
• Grossenbacher SK, Canter RJ, Murphy WJ. Natural killer cell immunotherapy to target stem-like tumor cells. Journal for Immunotherapy of Cancer. 2016;4:19. PubMed PMID: 27096096. Pubmed Central PMCID: 4835831. 10.1186/s40425-016-0124-2
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ .Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016 Aug 19;17(9):1025–1036. PubMed PMID: 27540992. 10.1038/ni.3518
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Rosell R Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res 2015 Dec;4(6):689–703. PubMed PMID: 26798578. Pubmed Central PMCID: PMC4700228.
   PubMedGoogle Scholar
• Tallerico R, Todaro M, Di Franco S, et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. Journal of Immunology (Baltimore, Md: 1950). 2013 Mar 1;190(5):2381–2390. PubMed PMID: 23345327. 10.4049/jimmunol.1201542
   PubMed Web of Science ®Google Scholar
• Castriconi R, Daga A, Dondero A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunology. 2009 Mar 15;182(6):3530–3539. PubMed PMID: 19265131. 10.4049/jimmunol.0802845
   PubMed Web of Science ®Google Scholar
• Pietra G, Manzini C, Vitale M, et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol. 2009 Jul;21(7):793–801. PubMed PMID: 19491215. 10.1093/intimm/dxp047
   PubMed Web of Science ®Google Scholar
• Yin T, Wang G, He S, et al. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cellular Immunology. 2016 Feb;300:41–45. PubMed PMID: 26677760. 10.1016/j.cellimm.2015.11.009
   PubMed Web of Science ®Google Scholar
• Ames E, Canter RJ, Grossenbacher SK, et al. NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. J Immunology. 2015 Oct 15;195(8):4010–4019. PubMed PMID: 26363055. Pubmed Central PMCID: 4781667. 10.4049/jimmunol.1500447
   PubMed Web of Science ®Google Scholar
• Ames E, Canter RJ, Grossenbacher SK, et al. Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. Oncoimmunology. 2015 Sep;4(9):e1036212. PubMed PMID: 26405602. Pubmed Central PMCID: 4570100. 10.1080/2162402X.2015.1008371
   Google Scholar
• Kozlowska AK, Tseng HC, Kaur K, et al. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-gamma after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother 2016 Sep;65(9):1085–1097. PubMed PMID: 27439500. Pubmed Central PMCID: PMC4996719. 10.1007/s00262-016-1866-x
   PubMed Web of Science ®Google Scholar
• Patel SA, Meyer JR, Greco SJ, et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunology. 2010 May 15;184(10):5885–5894. PubMed PMID: 20382885. 10.4049/jimmunol.0903143
   PubMed Web of Science ®Google Scholar
• Wang B, Wang Q, Wang Z, et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 2014 Oct 15;74(20):5746–5757. PubMed PMID: 25164008. 10.1158/0008-5472.CAN-13-3514
   PubMed Web of Science ®Google Scholar
• Kryczek I, Lin Y, Nagarsheth N, et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 2014 May 15;40(5):772–784. PubMed PMID: 24816405. Pubmed Central PMCID: 4032366. 10.1016/j.immuni.2014.03.010
   PubMed Web of Science ®Google Scholar
• Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs. 2009 Jan-Feb;1(1):12–25. PubMed PMID: 20046569. Pubmed Central PMCID: PMC2715180. 10.4161/mabs.1.1.7347
   PubMed Web of Science ®Google Scholar
• Michael HT, Ito D, McCullar V, et al. Isolation and characterization of canine natural killer cells. Veterinary Immunology and Immunopathology. 2013 Sep 15;155(3):211–217. PubMed PMID: 23876304. Pubmed Central PMCID: 4019669. 10.1016/j.vetimm.2013.06.013
   PubMed Web of Science ®Google Scholar
• Huang YC, Hung SW, Jan TR, et al. CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J Leukoc Biol. 2008 Dec;84(6):1501–1510. PubMed PMID: 18708592. 10.1189/jlb.0408255
   PubMed Web of Science ®Google Scholar
• Todaro M, D’Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunology. 2009 Jun 1;182(11):7287–7296. PubMed PMID: 19454726. 10.4049/jimmunol.0804288
   PubMed Web of Science ®Google Scholar